Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOS: Neoadjuvant osimertinib for resectable EGFR-mutant lung adenocarcinoma
ChiCTR1800016948Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Response rate. Started Aug 2018; status: recruiting.
02
Drugs
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800016948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016948.